Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.

Oncotarget - 1 Jun 2011

Passamonti Francesco, Maffioli Margherita, Caramazza Domenica, Cazzola Mario

Abstract excerpt

Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bone Marrow Neoplasms
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Association Studies

Share to Janus Kinase 2

Share to Leukemia

Share to Myeloproliferative Disorders

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 21646683
DOI: 10.18632/oncotarget.281
PMCID: PMC3248205

Genes

JAK2
ABL1
BCR
CBL
IDH1
IDH2
MPL
TET2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21646683-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.PMID 21646683Read ↗

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Semantic proximity Read ↗

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.Semantic proximity Read ↗

How many JAK inhibitors in myelofibrosis?Semantic proximity Read ↗

Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.Semantic proximity Read ↗

Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Semantic proximity Read ↗

Mutations, inflammation and phenotype of myeloproliferative neoplasmsSemantic proximity Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

New mutations and pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.